A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.

Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Leber B, Shastri A, Oganesian A, Keer HN, Azab M, Savona MR

Open source

DOI: 10.1080/14796694.2025.2468578
Published: 2025 Apr
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2468578,
  title = {A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.},
  author = {Garcia-Manero G and McCloskey J and Griffiths EA and Yee KWL and Zeidan AM and Al-Kali A and Deeg HJ and Sabloff M and Keating MM and Zhu N and Gabrail NY and Fazal S and Maly J and Odenike O and DeZern AE and O'Connell CL and Roboz GJ and Busque L and Buckstein R and Amin H and Leber B and Shastri A and Oganesian A and Keer HN and Azab M and Savona MR},
  year = {2025},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2025.2468578},
  url = {https://doi.org/10.1080/14796694.2025.2468578}
}

RIS

TY  - JOUR
TI  - A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
AU  - Garcia-Manero G
AU  - McCloskey J
AU  - Griffiths EA
AU  - Yee KWL
AU  - Zeidan AM
AU  - Al-Kali A
AU  - Deeg HJ
AU  - Sabloff M
AU  - Keating MM
AU  - Zhu N
AU  - Gabrail NY
AU  - Fazal S
AU  - Maly J
AU  - Odenike O
AU  - DeZern AE
AU  - O'Connell CL
AU  - Roboz GJ
AU  - Busque L
AU  - Buckstein R
AU  - Amin H
AU  - Leber B
AU  - Shastri A
AU  - Oganesian A
AU  - Keer HN
AU  - Azab M
AU  - Savona MR
PY  - 2025
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2025.2468578
UR  - https://doi.org/10.1080/14796694.2025.2468578
ER  -

APA

G, G., J, M., EA, G., KWL, Y., AM, Z., A, A., HJ, D., M, S., MM, K., N, Z., NY, G., S, F., J, M., O, O., AE, D., CL, O., GJ, R., L, B., R, B., H, A., B, L., A, S., A, O., HN, K., M, A., & MR, S. (2025). A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.. Future oncology (London, England). https://doi.org/10.1080/14796694.2025.2468578

Source records

pubmed · retrieved 2026-09-26T07:21:55.420Z